|
ChemBridge Research Laboratories, LLC (CRL) and ChemBridge Corporation today announced that CRL, ChemBridge, and Pfizer Inc. have amended their current strategic alliance agreement and simultaneously have entered into another discovery chemistry collaborative agreement. This expansion is based on the outstanding performance shown by both CRL and ChemBridge during the first two years of their current alliance with Pfizer. This new arrangement further extends CRL's and ChemBridge's strategic relationship with Pfizer until the end of 2008. It also expands the scale and the scope of their alliance beyond advanced screening libraries towards downstream discovery chemistry needs. These needs include hit-follow-up and medicinal chemistry support for the Pfizer Global Research and Development organization. Specific financial terms of the deal were not disclosed.
“We are extremely delighted to further enhance and broaden our strategic relationship with the world's largest pharmaceutical company,” said Eugene Vaisberg, Chairman and CEO of CRL and ChemBridge. “This major new deal is another proof of our entire organization's capabilities to succeed and excel in an increasingly competitive global discovery chemistry outsourcing market. Our business model draws on the complementary strengths of CRL's U.S. and ChemBridge's offshore (Russia) research sites. Our chemists in San Diego and Moscow are working as one integrated team, applying their combined intellectual contribution, creativity, and problem solving skills to numerous novel research intensive projects in synergy with the partner's scientists around the globe. The current collaborative relationship with our Pfizer colleagues has been extremely rewarding, which has helped the entire team of over 100 CRL and ChemBridge chemists to exceed very challenging 2002 and 2003 collaboration goals. I trust that the high scientific level, the dedication, and the commitment of our team ensure our ability to meet new challenges and continuously exceed Pfizer's expectations over the next five years. From the financial perspective, the new deal will support sustainable growth of both CRL and ChemBridge and further enhance our abilities to enter into new value added lead discovery and lead optimization collaborations.”
is a San Diego based discovery chemistry research company. Founded in 2000 as a spin-off of ChemBridge Corporation, CRL has quickly built a world-class research organization with a track record of exceeding goals on all its discovery chemistry collaborations including major multi-year strategic alliances with Pfizer and Merck. The list of CRL's partners also includes Eisai, GlaxoSmithKline, GNF, Memorial Sloan-Kettering Cancer Center, Tanabe, and Tularik. CRL's comprehensive discovery chemistry platform encompasses medicinal, efficient solution/solid phase, high-throughput, and versatile large scale chemistry, supported by automated purification/analytical/QC, computational chemistry, as well as complementary bioassay and early ADMET capabilities. With a core expertise in several important drug target super families and access to ChemBridge's entire enabling chemistry tools portfolio, CRL can tackle the most challenging hit-to-lead, lead optimization, and other collaborative discovery chemistry projects.
the parent company of CRL, is an established provider of innovative chemistry tools and contract research services for small molecule drug discovery. Privately held, ChemBridge was founded in Chicago in 1993 and has grown, self-funded, to a global company with over 350 employees and an impeccable track record of quality and deliverability. ChemBridge has its corporate headquarters in San Diego, European offices in the UK, a marketing agency in Japan, and operates a large, state-of-the-art offshore discovery chemistry research site in Moscow, Russia. Over 300 pharmaceutical and biotech companies and universities worldwide have taken advantage of ChemBridge's portfolio of discovery chemistry products and services including its library of 500,000 diverse drug-like small molecule compounds.
Together ChemBridge and CRL represent the industry's leading dedicated discovery chemistry research and outsourcing organization with over 400 scientists and professionals in its U.S. and offshore research sites.
ChemBridge Research Laboratories, LLC (CRL)
ChemBridge Corporation
Eugene Vaisberg
Chairman & CEO
Phone: 1-858-451-7400, ext. 110
back to press releases |
